MHLW Warns Use Of Chugai’s Pegasys In Patients With Interstitial Pneumonia
This article was originally published in PharmAsia News
Executive Summary
The Ministry of Health, Labor and Welfare has ordered Chugai Pharmaceutical to change labeling for interferon drug Pegasys (peginterferon Alfa-2a) for hepatitis C. MHLW contraindicated the use of the drug on patients with history of interstitial pneumonia. The decision is based on a comparison to other drugs; a higher hepatitis recurrence rate was reported among Pegasys patients with a history of interstitial pneumonia. (Click here for more - Japanese language
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.